Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug Zepbound through its direct-to-consumer platform, a move that will likely ease supply constraints and draw more patients to the company’s online portal.
Under the new offering, which is meant for patients paying on their own without insurance, 2.5-mg vials will cost $399 for one month’s supply, and 5-mg vials will cost $549. Lilly says the price is a discount off the currently available injectable pens, which carry a list price of $1,060 for a month’s supply; one analyst noted that the vial prices look to be in line with the net price of Zepbound pens, which is the amount that Lilly actually receives after rebates.
Dosages of Zepbound pens go up to 10 and 15 mg, but Lilly is only offering low-doses vials for now and will evaluate the possibility of selling high-dose vials later on, Patrik Jonsson, an executive vice president at Lilly, said in an interview.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
